Linda Robbie named as CRO BioAgilytix' COO

17 August 2022

Privately-held North Carolina, USA-based contract research organization (CRO) BioAgilytix has named Linda Robbie its new chief operating officer.

Dr Robbie has more than 25 years of experience with biomarker assay technologies, including 20 years spent in scientific leadership positions.

She joined BioAgilytix’ leadership team when the company was acquired in November 2019, serving as vice president and general manager of Boston operations, responsible for leading all bioanalytical services at BioAgilytix’s lab in the city. During this time, Dr Robbie directed all initiatives relating to science, technology. She was previously senior vice president of science and laboratory operations at UK-based Cambridge Biomedical.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK